GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares of 31¼ pence each on 13 April 2026 at prices between 2,154.00p and 2,180.00p, with a volume‑weighted average price of 2,169.64p.
The shares will be held as Treasury shares as part of GSK’s existing share buyback programme under a non‑discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 18,546,521 ordinary shares.
After this transaction, GSK holds 258,437,615 ordinary shares in treasury and has 4,057,753,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.37% of the company’s voting rights.
GSK plc reported that several senior executives and persons closely associated with them acquired small amounts of GSK ordinary shares through dividend reinvestment. The transactions reflect dividends paid on 9 April 2026 being automatically used to buy additional shares in investment accounts.
On the London Stock Exchange, shares were acquired at prices around £21.50–£21.70 per share on 9 and 10 April 2026. Participants included CEO Luke Miels, who acquired 2,393.328 shares at £21.5039, and multiple presidents and senior officers, each completing a single, routine purchase.
GSK plc reported encouraging early-stage results for mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate, in difficult-to-treat gynaecological cancers. In the phase 1 BEHOLD-1 trial, Mo-Rez monotherapy achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer at the highest doses tested.
The safety profile was described as manageable: very few patients stopped treatment because of treatment-related side effects, and serious side effects were mainly blood-related, which is typical for this drug class. Interstitial lung disease or pneumonitis occurred in 3% of patients and was mild to moderate. The median duration of response had not yet been reached at this interim analysis, suggesting responses may be durable but follow-up is ongoing.
On the back of these data, GSK plans to advance Mo-Rez into five pivotal global phase III trials in 2026 across ovarian and endometrial cancer settings, including earlier-line and maintenance use. This programme underscores GSK’s broader oncology strategy focused on antibody-drug conjugates and women’s cancers.
GSK plc reports that on 10 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,157.00p and 2,196.00p, with a volume-weighted average price of 2,182.28p, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 18,221,521 ordinary shares. Following this latest transaction, it holds 258,112,615 shares in treasury and has 4,058,078,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.36% of voting rights, a figure shareholders can use when assessing notification thresholds.
GSK plc reports routine insider share acquisitions linked to its Share Reward Plan. Several senior executives and persons closely associated with them acquired small numbers of GSK ordinary shares of 31¼ pence each through the automatic reinvestment of dividends paid on 9 April 2026.
Transactions were executed on the London Stock Exchange at prices of £21.3387 and £21.5039 per share, with individual amounts ranging from low single-digit shares to just over 1,000 shares. These acquisitions reflect dividend reinvestment rather than open-market buying decisions.
GSK plc reports that on 09 April 2026 it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing buyback programme. The volume-weighted average price was 2,139.38p, with prices between 2,124.00p and 2,158.00p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 17,896,521 ordinary shares. After this transaction, it holds 257,787,615 ordinary shares in treasury and has 4,058,396,834 ordinary shares in issue, all carrying voting rights.
GSK states that the total number of voting rights is 4,058,396,834 and confirms that, following this purchase, ordinary shares held in treasury represent 6.35% of its voting rights.
GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The plan transaction on 2026-04-07 involved 8.551 ADS at a price of $55.8400 per ADS on the New York Stock Exchange.
GSK plc reports that, acting through BNP Paribas, it repurchased 330,000 ordinary shares on 08 April 2026 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 2,105.00p and 2,140.00p per share, with a volume‑weighted average price of 2,125.45p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, the company has bought back 17,566,521 ordinary shares. After this transaction, GSK holds 257,457,615 shares in treasury and has 4,058,726,834 ordinary shares in issue, which is also the total number of voting rights. The company states that treasury shares now represent 6.34% of voting rights, a figure relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that China’s National Medical Products Administration has approved Exdensur (depemokimab) as an add-on therapy for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) whose disease is not adequately controlled by systemic corticosteroids and/or surgery. Exdensur is described as the first and only ultra-long-acting biologic in China for CRSwNP and is given twice a year alongside intranasal corticosteroids.
The approval is based on phase III ANCHOR-1 and ANCHOR-2 trials, which showed statistically significant reductions in nasal polyp size and nasal obstruction scores compared with placebo plus standard of care over 52 weeks. Across these trials, depemokimab was reported as well-tolerated with a similar rate and severity of side effects to placebo plus standard care. Exdensur already has approvals for severe asthma in multiple regions, and depemokimab is being studied in additional type 2 inflammation–driven diseases, broadening GSK’s respiratory portfolio.
GSK plc reports that, acting through BNP Paribas, it repurchased 335,000 ordinary shares of 31¼ pence each on 7 April 2026 as part of its existing share buyback programme.
The shares were bought at prices between 2,084.00p and 2,134.00p, with a volume‑weighted average price of 2,113.08p, and will be held as Treasury shares.
Since 17 February 2026, GSK has bought 17,236,521 shares under this programme. After this latest purchase, it holds 257,127,615 shares in treasury and has 4,059,056,834 shares in issue (excluding treasury), which equals 4,059,056,834 voting rights. Treasury shares represent 6.33% of total voting rights under DTR 5.5.1R.